You are here: Industry Insights > HoFH

News List

FDA approves add-on therapy for patients with genetic form of severely high cholesterol americanpharmaceuticalreview
April 07, 2021
FDA has approved Praluent (alirocumab) injection for adult patients with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol. Praluent is not intended to be used alone but instead added to other ...
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol drugs.com
September 23, 2020
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for Priority Review a Biologics License Application for evinacumab as an adjunct to other lipid-lowering therapies in patients with homozygous...
FDA Accepts Evinacumab BLA for HoFH americanpharmaceuticalreview
August 17, 2020
Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a Biologics License Application (BLA) for evinacumab as an adjunct to other lipid-lowering therapies in patients with homozygous familial ...